Meta-analysis of NFKB1-94 ATTG Ins/Del Polymorphism and Risk of Breast Cancer

Curr Drug Metab. 2020;21(3):221-225. doi: 10.2174/1389200221666200310113118.

Abstract

Background: Breast cancer (BC) accounts for one of the most prevalent malignancies in the world. Inflammatory molecules modulate tumor microenvironment in BC that promotes tumor growth and metastasis. NF-κB (a transcription factor) that regulates multiple immune functions and acts as a crucial mediator of inflammatory responses.

Objective: The present study is aimed to quantitatively summarize the relation of NFKB1-94 ATTG (I, insertion/D, deletion) variant and risk of BC.

Methods: Further, the meta-analysis includes three independent case-control investigations that focus on NFKB1-94, ATTG I/D polymorphism, and BC patients. Web of Science, PubMed and Embase databases were used to retrieve relevant data. OR and 95% confidence interval of pooled studies were analyzed by using the MetaGenyo web tool.

Results: This study revealed a high heterogeneity. In all three genetic comparison models, the NFKB1-94 ATTG I/D variant is not related to the risk of BC. Further, no publication bias on the connection between NFKB1-94 ATTG I/D variant and risk of BC was observed.

Conclusion: To summarize, our meta-analysis demonstrates that the NFKB1-94 ATTG I/D polymorphism is not a major risk factor for BC.

Keywords: ATTG I/D polymorphism; Breast cancer; NFKB1-94; inflammation; meta-analysis; transcription factor..

Publication types

  • Meta-Analysis

MeSH terms

  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • NF-kappa B p50 Subunit / genetics*
  • Polymorphism, Genetic
  • Risk Factors

Substances

  • NF-kappa B p50 Subunit